Based on multiplex assays of plasma and tumor material from the rodent tumor studies contained within this paper, we discovered that these drug combination treatments caused a compensatory activation of ERBB1/2/4-PI3K-AKT in the liver and colorectal tumor cells surviving the (sorafenib/regorafenib + sildenafil) drug treatments. This evidence concerns the gene EGFR and neoplasm.